Director/PDMR Shareholding

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 On 27 March 2015, the individuals listed below, who are all persons discharging
managerial responsibilities, were granted awards over the Company's ordinary
shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca
Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and
the AstraZeneca Investment Plan (AZIP). One ADS equals one ordinary share.

 Name     Shares         Shares         Shares      Award price per share
          awarded under  awarded under  awarded
          AZDBP          AZPSP          under AZIP
 Pascal    13,482         104,764        17,460      4762p
Soriot
 Marc      7,111          45,880         7,646       4762p
Dunoyer
 Briggs    2,620          22,457         3,742       $70.58
Morrison
 Luke      1,570          24,412         4,068       4762p
Miels

The AZDBP award represents the portion of each individual's annual bonus for
2014 that they are required to defer into shares. The shares are subject to a
three-year holding period (27 March 2015 to 26 March 2018).

The AZPSP award is subject to a combination of performance measures focused on
our scientific, commercial and financial performance assessed over a three-year
performance period (1 January 2015 to 31 December 2017). The award will vest on
the third anniversary of the date on which it was granted, except for awards to
Executive Directors, which will be subject to a further two-year holding period
before the award vests.

The AZIP award is subject to two performance hurdles relating to dividend and
dividend cover; both must be achieved in each year of the four-year performance
period (1 January 2015 to 31 December 2018) for the award to vest.  The award is
subject to a four-year holding period, commencing at the end of the performance
period.

Details of the performance measures that relate to the AZPSP and AZIP awards are
available on the Company's website at www.astrazeneca.com/Investors/Annual
-reports.

On 30 March 2015, the interest of Dr Briggs Morrison, a person discharging
managerial responsibilities, in the American Depositary Shares (ADSs) of
AstraZeneca PLC changed as detailed below.  One ADS equals one ordinary share.

The change in interest relates to the vesting of awards of shares made in March
2012 under the AstraZeneca Performance Share Plan and the AstraZeneca Restricted
Share Plan as set out in the table below.

In respect of the award of shares under the AstraZeneca Performance Share Plan,
following the application of performance measures specified at the time of
grant, Dr Morrison has become beneficially entitled to 50% of the shares
originally awarded. In accordance with the plan rules, any unvested part of the
award has immediately and irrevocably lapsed.

In respect of the award of shares under the AstraZeneca Restricted Share Plan,
in accordance with the terms of the award, Dr Morrison has become beneficially
entitled to all of the shares originally awarded.

Sufficient vested shares have been withheld to cover certain tax obligations
arising on the vesting and the net number of shares has been delivered into a
personal brokerage account.

 Plan              Shares   Shares   Shares withheld  Net shares received
                   awarded  vested
 AstraZeneca        43,340   21,670   10,452           11,218
Performance Share
Plan
 AstraZeneca        24,724   24,724   11,924           12,800
Restricted Share
Plan

For tax purposes, the fair market value of the shares at vest was $70.07 per
share being the closing price of AstraZeneca ADSs on the last trading day
preceding the vesting day.



A C N Kemp

Company Secretary

30 March 2015